Dr. Christopher Andrew Barker, MD

Dr. Barker practices at The New York Proton Center in New York, New York.

Dr. Barker's NPI, 1598959058, was assigned on August 28, 2007. Dr. Barker graduated from University Of Florida College Of Medicine in 2006. Dr. Barker holds New York license 244819.

Dr. Barker's primary practice is The New York Proton Center, at 225 E 126th St, New York, NY 10035 in New York County. The practice phone is (646) 968-9064.

Dr. Barker's primary practice is The New York Proton Center in New York, New York. Dr. Barker is also affiliated with Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. Barker to 1 more hospital and 5 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Barker practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Barker's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Barker is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Barker's licenses on file in 4 states: New York, Florida, New Jersey and Connecticut.

Dmand AI lists bone cancer radiation and lymphoma radiation among the conditions Dr. Barker treats.

CMS data shows 2,426 Medicare services from Dr. Barker across 18 procedure codes in 2024, for 782 Medicare patients. Medicare paid $293,182 for them.

CMS counts 782 Medicare patients who saw Dr. Barker in 2024. The largest group is 65 to 74, with 344 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Barker's median patient age at 68, with 42% women.

In 2024, Dr. Barker wrote 119 Medicare Part D claims for 63 patients. 76% of them were for generic drugs. CMS names the drug for 42 of them, across 2 drugs with 11 or more claims each, at $483 in total drug cost. In 2023, CMS named 44 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Barker for performance year 2024, reported as part of a group. Dr. Barker accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Barker as offering telehealth.

Dmand AI links 93 papers to Dr. Barker, published from 2009 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Skin Neoplasms, Melanoma and Brachytherapy. Dr. Barker has published most often in Int J Radiat Oncol Biol Phys. Dr. Barker's most frequent co-authors are Alexander Noor Shoushtari, MD, Jasmine H. Francis, MD and David H H. Abramson, MD.

Dmand AI links Dr. Barker to 14 clinical trials, 8 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Neoplasms, Squamous Cell, Carcinoma, Squamous Cell and Carcinoma, Merkel Cell. Memorial Sloan Kettering Cancer Center sponsors the most, 10.

CMS Open Payments shows 36 general payments to Dr. Barker from 3 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 90% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $21,428.

Dr. Barker graduated from University Of Florida College Of Medicine in 2006. Dr. Barker is a member of AOA, ASTRO and ASCO.

Dr. Barker is in network with 15 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.